Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2018 | How reliable is NGS in diagnosing AML?

Christopher Gibson • 12 Sep 2018
SOHO 2018
Acute Myeloid Leukemia Leukemia

Christopher Gibson, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses the reliability of next-generation sequencing (NGS) at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX. Dr Gibson explains that results from NGS have been reliable as the mutations seen are those that are present in Acute myeloid leukemia (AML). Dr Gibson also questions the relevance on the results and how this is entirely dependent on expert interpretation.

More from Christopher Gibson

1:42
The superior sequencing technique: NGS versus SGS
Christopher Gibson • 12 Sep 2018
3:11
Uses of NGS in AML
Christopher Gibson • 12 Sep 2018
3:40
Pros and cons of next-generation sequencing
Christopher Gibson • 12 Sep 2018

Related Videos

2:05
Investigating mutation order in AML using single-cell sequencing
Ravindra Majeti • 8 Apr 2024
3:12
An epitope editing approach to enable the use of targeted immunotherapy in AML
Gabriele Casirati • 9 Apr 2024
0:59
Developing LSC-targeting agents in AML: progress and current therapeutic capacity
Ravindra Majeti • 8 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
The content of VJHemOnc is intended for healthcare professionals